Page last updated: 2024-11-06

1-nitro-2-phenylethane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-nitro-2-phenylethane: component of Aniba canelilla essential oil with antinociceptive activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Anibagenus[no description available]LauraceaeA family of mainly aromatic evergreen plants in the order Laurales. The laurel family includes 2,200 species in 45 genera and from these are derived medicinal extracts, essential oils, camphor and other products.[MeSH]

Cross-References

ID SourceID
PubMed CID80208
CHEMBL ID4572176
SCHEMBL ID264237
MeSH IDM0537130

Synonyms (27)

Synonym
nsc 23854
einecs 228-094-0
1-nitro-2-phenylethane
6125-24-2
benzene, (2-nitroethyl)-
nsc-23854
nsc23854
(2-nitroethyl)benzene
FT-0650568
2-nitroethylbenzene
AKOS006240249
SCHEMBL264237
1-phenyl-2-nitroethane
2-phenylnitroethane
1-(2-nitroethyl)benzene
DTXSID30210155
2-nitro-ethyl-benzene
mfcd00210449
1-(phenyl) 2-nitroethane
CS-W021067
A923978
SY043104
1-(phenyl)2-nitroethane
AS-33131
EN300-65029
CHEMBL4572176
Z995234780

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In the writhing test this compound was dosed at 15, 25 and 50 mg/kg reducing the abdominal writhes in a significant manner; in the hot plate test it was assayed at 50, 100 and 200 mg/kg producing no alterations in the latency time when compared to the control; and in the formalin test the 1-nitro-2-phenylethane was tested at 50 and 25 mg/kg decreasing significantly the second phase of the algic stimulus."( Antinociceptive activity of 1-nitro-2-phenylethane, the main component of Aniba canelilla essential oil.
Cardoso, AS; Carvalho, JC; da Silva, JK; de Lima, AB; Maia, JG; Santana, MB; Sousa, PJ, 2009
)
0.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
FlavodoxinHelicobacter pylori 26695MIC176.66672.90002.90002.9000AID1568972; AID1568973; AID1568974
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1568983Therapeutic index, ratio of MCC50 for human HeLa cells to MIC for inhibition of flavodoxin in metronidazole-resistant Helicobacter pylori isolate 1 assessed as reduction in bacterial growth
AID1568974Inhibition of flavodoxin in Helicobacter pylori ATCC 700392 26695 assessed as reduction in bacterial growth measured after 48 hrs by resazurin staining-based microdilution method
AID1568972Inhibition of flavodoxin in Helicobacter pylori SS1 assessed as reduction in bacterial growth measured after 48 hrs by resazurin staining-based microdilution method
AID1568986Therapeutic index, ratio of MCC50 for human HeLa cells to MIC for inhibition of flavodoxin in clarithromycin/metronidazole-resistant Helicobacter pylori isolate 4 assessed as reduction in bacterial growth
AID1568976Therapeutic index, ratio of MCC50 for human HeLa cells to MIC for inhibition of flavodoxin in Mnz-resistant Helicobacter pylori NCTC 11637 ATCC 43504 assessed as reduction in bacterial growth
AID1569037Effect on growth of Staphylococcus aureus ATCC 1228 after 48 hrs by resazurin-dye based microdilution assay
AID1568975Therapeutic index, ratio of MCC50 for human HeLa cells to MIC for inhibition of flavodoxin in Helicobacter pylori SS1 assessed as reduction in bacterial growth
AID1569035Binding affinity to Helicobacter pylori flavodoxin by isothermal titration calorimetric method
AID1568971Cytotoxicity against human HeLa cells assessed as reduction in cell viability by XTT assay
AID1568988Therapeutic index, ratio of MCC50 for human HeLa cells to MIC for inhibition of flavodoxin in clarithromycin/metronidazole-resistant Helicobacter pylori isolate 6 assessed as reduction in bacterial growth
AID1568987Therapeutic index, ratio of MCC50 for human HeLa cells to MIC for inhibition of flavodoxin in rifampicin-resistant Helicobacter pylori isolate 5 assessed as reduction in bacterial growth
AID1569036Effect on growth of Escherichia coli DH5[alpha] after 48 hrs by resazurin-dye based microdilution assay
AID1568973Inhibition of flavodoxin in Mnz-resistant Helicobacter pylori NCTC 11637 ATCC 43504 assessed as reduction in bacterial growth measured after 48 hrs by resazurin staining-based microdilution method
AID1568977Therapeutic index, ratio of MCC50 for human HeLa cells to MIC for inhibition of flavodoxin in Helicobacter pylori ATCC 700392 26695 assessed as reduction in bacterial growth
AID1568985Therapeutic index, ratio of MCC50 for human HeLa cells to MIC for inhibition of flavodoxin in metronidazole-resistant Helicobacter pylori isolate 3 assessed as reduction in bacterial growth
AID1568984Therapeutic index, ratio of MCC50 for human HeLa cells to MIC for inhibition of flavodoxin in metronidazole-resistant Helicobacter pylori isolate 2 assessed as reduction in bacterial growth
AID1569034Binding affinity to Helicobacter pylori flavodoxin by thermal upshift assay
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (6.25)29.6817
2010's11 (68.75)24.3611
2020's4 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.69 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.22 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]